By week 52, reductions in hsCRP of up to 43% vs placebo were seen for all semaglutide treatment groups that were either statistically significant at the 5% level or close to significance.
← all excerpts
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
2
—
—
The sentences
Numerically lower reductions were seen in the group with normal baseline ALT that generally failed to reach statistical significance.